Misleading Short-Seller Report Allegations Rebutted by ADMA Biologics
ADMA is trading near its 52-week low of $10.9 (6.7% above the low) on elevated volume (7.2× avg).
Summary
ADMA Biologics has officially responded to a short-seller report issued by Culper Research on March 24, 2026, which disclosed a short position in ADMA. The company vehemently refutes the report's claims, characterizing them as "speculative assertions" derived from unreliable sources and containing "numerous misleading, false and inaccurate statements." This event is significant as it directly challenges the integrity of ADMA's financial reporting and operational disclosures. Traders will closely monitor how the market weighs these allegations against the company's strong rebuttal. Future developments, including any further details from either party or potential regulatory interest, will be key catalysts.
At the time of this announcement, ADMA was trading at $11.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $10.90 to $25.67. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.